ReviewSeminars in nuclear medicine2022
Clinical Management of COVID-19 Patients - An Update.
Review in Seminars in nuclear medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Efficacy of tenofovir on clinical outcomes of COVID-19 patients: a systematic review.BMC infectious diseases · 2025Pooled it
- Taste dysfunction as a predictor of depression in schizophrenia: A systematic review and meta-analysis.PloS one · 2024Pooled it
- COVID-19 and the Immune Response: A Multi-Phasic Approach to the Treatment of COVID-19.International journal of molecular sciences · 2022Pooled it
- Patient Experience and Caregiver Involvement in COVID-19 Care Pathways: Revealing System Blind Spots Through a Life-Events Calendar Approach.Healthcare (Basel, Switzerland) · 2026Article
- Current Approaches to the Management of Acute Surgical and Medical Emergencies: A Structured Narrative Review.Cureus · 2026Review
- Discovery of potential antiviral compounds and accelerating the therapeutic discovery against monkeypox virus.Scientific reports · 2026Article
- Observational
- Predictors for cause-specific and timing of deaths in patients with COVID-19: a cohort study in Taiwan.BMC infectious diseases · 2024Article
- Article
- COVID-19 Associated Cardiovascular Disease-Risks, Prevention and Management: Heart at Risk Due to COVID-19.Current issues in molecular biology · 2024Review
- Lipidome is a valuable tool for the severity prediction of coronavirus disease 2019.Frontiers in immunology · 2024Article
- New insights into the pathogenesis of SARS-CoV-2 during and after the COVID-19 pandemic.Frontiers in immunology · 2024Review
- Effect of Vitamin D in Long COVID Patients.International journal of environmental research and public health · 2023Article
- Secondary pulmonary infection byWorld journal of clinical cases · 2023Article
- Long-term monitoring of COVID-19 prevalence in raw and treated wastewater in Salvador, the largest capital of the Brazilian Northeast.Scientific reports · 2023Article
- Exploration of the Shared Molecular Mechanisms between COVID-19 and Neurodegenerative Diseases through Bioinformatic Analysis.International journal of molecular sciences · 2023Article
- Efficacy and Safety of Inhaled Ethanol in Early-Stage SARS-CoV-2 Infection in Older Adults: A Phase II Randomized Clinical Trial.Pharmaceutics · 2023Article
- COVID-19-Associated Erythema Nodosum Detected on FDG PET/CT.Diagnostics (Basel, Switzerland) · 2023Article
- Molecular Diagnosis of COVID-19; Biosafety and Pre-analytical Recommendations.Iranian journal of pathology · 2023Review
- Synergistic fight against future pandemics: Lessons from previous pandemics.Le infezioni in medicina · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 virus may cause COVID-19 disease, which causes mild-to-moderate disease in 80% of laboratory-confirmed cases which may be community-managed. A considerable age-dependent mortality is seen among elderly and other at-risk populations but among young and healthy individuals it is < 0.5%. Long-term health issues have been reported following severe COVID-19 requiring hospitalization as well as after cases of mild COVID-19 without hospitalization. Upon receiving COVID-19 suspected patients at hospitals, patients should be isolated and PPE should be worn by all health staff when in contact with the patients. Additionally, patients are tested for the presence of SARS-CoV-2 RNA by PCR, and blood samples are drawn. Imaging is not pivotal for the diagnosis, but chest X-ray is a relevant examination for all and is used to determine severity and treatment need Abnormal findings on CT scans are found in most patients, most frequently peripheral ground-glass opacity and bilateral patchy shadowing are present. Patients are, according to their needs and risks, treated with oxygen therapy, anticoagulation therapy, steroids, antivirals, or immunosupressive drugs on special indications. Convalescent plasma therapy and monoclonal antibodies have a limited role in the treatment, mostly in severely immunocompromised patients. Patients with long-term sequelae should be evaluated in a post-COVID outpatient clinic. The most frequent reported symptoms include cognitive impairment, dyspnea, loss of smell and taste, and mental and physical fatigue although a wide spectrum of symptoms from other organ systems are also reported. The current treatment is based on symptom relief and rehabilitation as there is no documented specific medical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.